Enliven Therapeutics Announces Positive Phase 1 Trial Results

The latest announcement is out from Enliven Therapeutics ( (ELVN) ).

On June 13, 2025, Enliven Therapeutics announced positive data from its Phase 1 ENABLE clinical trial for ELVN-001, a treatment for chronic myeloid leukemia. The trial showed a 47% major molecular response rate by 24 weeks, with ELVN-001 demonstrating favorable safety and tolerability compared to existing therapies. The data suggests ELVN-001 could be a promising option for patients needing improved long-term disease management, positioning the company well in the CML treatment landscape.

The most recent analyst rating on (ELVN) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Enliven Therapeutics stock, see the ELVN Stock Forecast page.

Spark’s Take on ELVN Stock

According to Spark, TipRanks’ AI Analyst, ELVN is a Underperform.

Enliven Therapeutics’ stock is challenged by its early-stage financial profile with no revenue and ongoing losses. Despite strong liquidity, the reliance on external financing and lack of profitability weigh heavily. Technical indicators reinforce a cautious approach, as the stock shows bearish trends. Valuation metrics further reflect the typical risk profile of a biotech company in development.

To see Spark’s full report on ELVN stock, click here.

More about Enliven Therapeutics

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The company primarily targets chronic myeloid leukemia (CML) with its product ELVN-001, aiming to address treatment resistance and intolerance in heavily pretreated patient populations.

Average Trading Volume: 350,919

Technical Sentiment Signal: Sell

Current Market Cap: $962M

For an in-depth examination of ELVN stock, go to TipRanks’ Overview page.